https://www.bmj.com/content/374/bmj.n2086 Skip to main content Intended for healthcare professionals * Subscribe * My Account + My email alerts * BMA member login Login + Username * [ ] Password * [ ] Forgot your log in details? Need to activate [Login] ------------------------------------------------------------- BMA Member Log In Log in via OpenAthens Log in via your institution Edition: US * UK * South Asia * International Our company Toggle navigation The BMJ logo Site map Search Search form [ ]Search Search * Advanced search * Search responses * Search blogs Toggle top menu * covid-19 * Research + At a glance + Research papers + Research methods and reporting + Minerva + Research news * Education + At a glance + Clinical reviews + Practice + Minerva + Endgames + State of the art + What your patient is thinking + Rapid recommendations + Student * News & Views + At a glance + News + Features + Editorials + Analysis + Observations + Opinion + Head to head + Editor's choice + Letters + Obituaries + Views and reviews + Careers + Rapid responses * Campaigns + At a glance + Better evidence + Climate change + Divestment from fossil fuels + Patient and public partnership + Too much medicine + Wellbeing + The BMJ Collections * Jobs + Doctor Jobs UK + Hospital Jobs UK + GP Jobs UK + International Jobs + North America Jobs * Archive * For authors * Hosted 1. News & Views 2. Covid-19: FDA set to... 3. Covid-19: FDA set to grant full approval to Pfizer vaccine without public discussion of data News Covid-19: FDA set to grant full approval to Pfizer vaccine without public discussion of data BMJ 2021; 374 doi: https://doi.org/10.1136/bmj.n2086 (Published 20 August 2021) Cite this as: BMJ 2021;374:n2086 Read our latest coverage of the coronavirus pandemic Linked Opinion Does the FDA think these data justify the first full approval of a covid-19 vaccine? * Article * Related content * Metrics * Responses * Peer review * Loading 1. Gareth Iacobucci 1. The BMJ Transparency advocates have criticised the US Food and Drug Administration's (FDA) decision not to hold a formal advisory committee meeting to discuss Pfizer's application for full approval of its covid-19 vaccine. Last year the FDA said it was "committed to use an advisory committee composed of independent experts to ensure deliberations about authorisation or licensure are transparent for the public."1 But in a statement, the FDA told The BMJ that it did not believe a meeting was necessary ahead of the expected granting of full approval. "The FDA has held numerous meetings of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) related to covid-19 vaccines, including a 22 October 20202 meeting to discuss, in general, the development, authorisation, and licensure of covid-19 vaccines," an FDA spokesperson said. "The FDA also has held meetings of the VRBPAC on all three covid-19 vaccines authorised for emergency use and does not believe a meeting is needed related to this biologics license application." The spokesperson added, "The Pfizer BioNTech covid-19 vaccine was discussed at the VRBPAC meeting on 10 December 2020.3 If the agency had any questions or concerns that required input from the advisory committee members we would have scheduled a meeting to discuss." The vaccine has already been rolled out to millions of Americans through an emergency use authorisation. Companies typically apply for full approval after a longer period has elapsed so that more data are available for review. But with the US government indicating this week that it plans to start making booster shots widely available next month, experts said the decision not to meet to discuss the data was politically driven. Data scrutiny Kim Witczak, a drug safety advocate who serves as a consumer representative on the FDA's Psychopharmacologic Drugs Advisory Committee,4 said the decision removed an important mechanism for scrutinising the data. "These public meetings are imperative in building trust and confidence especially when the vaccines came to market at lightning speed under emergency use authorisation," she said. "The public deserves a transparent process, especially as the call for boosters and mandates are rapidly increasing. These meetings offer a platform where questions can be raised, problems tackled, and data scrutinised in advance of an approval." Witczak is one of the more than 30 signatories of a citizen petition5 calling on the FDA to refrain from fully approving any covid-19 vaccine this year to gather more data. She warned that without a meeting "we have no idea what the data looks like." "It is already concerning that full approval is being based on 6 months' worth of data despite the clinical trials designed for two years," she said. "There is no control group after Pfizer offered the product to placebo participants before the trials were completed. "Full approval of covid-19 vaccines must be done in an open public forum for all to see. It could set a precedent of lowered standards for future vaccine approvals." Public discussion Diana Zuckerman, president of the National Center for Health Research, who has also spoken at recent VRBPAC meetings, told The BMJ , "It's obvious that the FDA has no intention of hearing anyone else's opinion. But if you make decisions behind closed doors it can feed into hesitancy. It's important to have a public discussion about what kind of data are there and what the limitations are. As we think about risk versus benefit, we need to know." Joshua Sharfstein, vice dean for public health practice and community engagement at the Johns Hopkins Bloomberg School of Public Health and former FDA deputy commissioner during the Obama administration, said that advisory committee meetings were more than just a way of receiving scientific input from outside experts. "It's also an opportunity to educate the public about the important work that the FDA has done reviewing an enormous amount of data about a product," he told The BMJ. "It's a chance for questions to be asked and answered, building public confidence. "If there are no advisory committee meetings prior to licensure, the FDA should consider taking extra steps to explain the basis of its decisions to the public." On 18 August, before the news that the FDA would not be holding a formal committee meeting, the president of the Infectious Diseases Society of America Barbara Alexander praised the impact of the VRBPAC meetings as "a critical and necessary part" of the process for assessing whether to give booster doses.6 Footnotes * Correction: We amended the reference list on 20 August 2021 to replace reference 5. This article is made freely available for use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained. https://bmj.com/coronavirus/usage References 1. | Shah A, Marks P, Hahn S. Ensuring the safety and effectiveness of a covid-19 vaccine. www.healthaffairs.org/do/10.1377/ hblog20200814.996612/full. 2. | FDA. Vaccines and related biological products advisory committee, October 22 2020, meeting announcement. 2020. www.fda.gov/ advisory-committees/advisory-committee-calendar/ vaccines-and-related-biological-products-advisory-committee-october-22-2020-meeting-announcement . 3. | FDA. Vaccines and related biological products advisory committee, December 10 2020, meeting announcement. 2020. www.fda.gov/ advisory-committees/advisory-committee-calendar/ vaccines-and-related-biological-products-advisory-committee-december-10-2020-meeting-announcement . 4. | FDA. Psychopharmacologic drugs advisory committee roster. www.fda.gov/advisory-committees/ psychopharmacologic-drugs-advisory-committee/ psychopharmacologic-drugs-advisory-committee-roster. 5. | Wastila L, Doshi P, Merchant M, Witczak K. Why we petitioned the FDA to refrain from fully approving any covid-19 vaccine this year. BMJ Opinion. 8 June 2021. https://blogs.bmj.com/bmj/2021/06 /08/ why-we-petitioned-the-fda-to-refrain-from-fully-approving-any-covid-19-vaccine-this-year . 6. | IDSA. Response to plan for supplemental vaccine doses for vaccinated individuals. 18 August 2021. www.idsociety.org/ news-publications-new/articles/2021/ response-to-plan-for-supplemental-vaccine-doses-for-vaccinated-individuals . View Abstract * Tweet Widget * Facebook Like Article tools PDF2 responses * Respond to this article * Print * Alerts & updates Article alerts Please note: your email address is provided to the journal, which may use this information for marketing purposes. Log in or register: Username * [ ] Password * [ ] [Log in] Register for alerts If you have registered for alerts, you should use your registered email address as your username * Citation tools Download this article to citation manager Gareth Iacobucci Iacobucci G. Covid-19: FDA set to grant full approval to Pfizer vaccine without public discussion of data BMJ 2021; 374 :n2086 doi:10.1136/bmj.n2086 + BibTeX (win & mac)Download + EndNote (tagged)Download + EndNote 8 (xml)Download + RefWorks Tagged (win & mac)Download + RIS (win only)Download + MedlarsDownload Help If you are unable to import citations, please contact technical support for your product directly (links go to external sites): + EndNote + ProCite + Reference Manager + RefWorks + Zotero * Request permissions * Author citation * Articles by Gareth Iacobucci * Add article to BMJ Portfolio Email to a friend Forward this page Thank you for your interest in spreading the word about The BMJ. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Username * [ ] Your Email * [ ] Send To * [ ] [ ] [ ] You are going to email the following Covid-19: FDA set to grant full approval to Pfizer vaccine without public discussion of data Your Personal Message [ ] [ ] [ ] CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. [Send] * UK jobs * International jobs Loading Frome Medical Practice: Salaried GP Crewkerne Health Centre: GP Opportunity at Crewkerne Health Centre Lakeside Health Group: Salaried GPs and GP Partners Jobs Leeds Teaching Hospitals NHS Trust: Consultant in Haematology East London NHS Foundation Trust: CAMHS Consultant Psychiatrist View more [CROSSMARK_Color_hori] This week's poll Read related article See previous polls Back to top Follow us on * Twitter * Facebook * YouTube * Pinterest * RSS Content links * Collections * Health in South Asia * Women's, children's & adolescents' health * Zika virus * Research * Education * News and views * BMJ Opinion * Rapid responses * Archive About us * About us * Editorial staff * BMJ in the USA * BMJ in South Asia * Advisers * Policies * Submit your paper Resources * Authors * Reviewers * BMA members * Readers * Subscribers * Advertisers and sponsors * Media * Recruiters Explore BMJ * Our company * BMJ Careers * BMJ Learning * BMJ Masterclasses * BMJ Journals * BMJ Student * Academic edition of The BMJ * BMJ Best Practice * The BMJ Awards My account * Email alerts * Activate subscription Information * Contact us * Complaints * Cookie settings * Cookie Policy * Privacy policy * Website T&Cs * Revenue Sources * HighWire Press * Sitemap Copyright (c) 2021 BMJ Publishing Group Ltd Jing ICPBei 15042040Hao -3 *